NO20052714L - Fremgangsmater og materialer for behandling av inflammatoriske tilstander - Google Patents

Fremgangsmater og materialer for behandling av inflammatoriske tilstander

Info

Publication number
NO20052714L
NO20052714L NO20052714A NO20052714A NO20052714L NO 20052714 L NO20052714 L NO 20052714L NO 20052714 A NO20052714 A NO 20052714A NO 20052714 A NO20052714 A NO 20052714A NO 20052714 L NO20052714 L NO 20052714L
Authority
NO
Norway
Prior art keywords
methods
materials
inflammatory conditions
treating inflammatory
mammal
Prior art date
Application number
NO20052714A
Other languages
English (en)
Other versions
NO20052714D0 (no
Inventor
Rikard Holmdahl
Lars T Hellmann
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Publication of NO20052714D0 publication Critical patent/NO20052714D0/no
Publication of NO20052714L publication Critical patent/NO20052714L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)

Abstract

Oppfinnelsen tilveiebringer metoder og materialer for behandling av inflammatoriske tilstander. Spesifikt tilveiebringer oppfinnelsen polypeptider, isolerte nukleinsyrer, vertsceller og metoder som kan anvendes til å indusere en antistoffrespons hos et pattedyr overfor et antigen så som C5 eller C5a. Metodene og materialene beskrevet her kan for eksempel anvendes til redusering av virkningene av C5a i et pattedyr ved redusering av mengden av total og reseptorbundet C5a i pattedyret.
NO20052714A 2002-12-02 2005-06-06 Fremgangsmater og materialer for behandling av inflammatoriske tilstander NO20052714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43027802P 2002-12-02 2002-12-02
PCT/IB2003/006344 WO2004050111A2 (en) 2002-12-02 2003-12-01 Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment

Publications (2)

Publication Number Publication Date
NO20052714D0 NO20052714D0 (no) 2005-06-06
NO20052714L true NO20052714L (no) 2005-08-10

Family

ID=32469435

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052714A NO20052714L (no) 2002-12-02 2005-06-06 Fremgangsmater og materialer for behandling av inflammatoriske tilstander

Country Status (15)

Country Link
US (2) US7361742B2 (no)
EP (1) EP1569958B1 (no)
JP (1) JP2006507834A (no)
KR (1) KR20050090390A (no)
CN (1) CN1745098A (no)
AT (1) ATE423133T1 (no)
AU (1) AU2003288472A1 (no)
CA (1) CA2508302A1 (no)
DE (1) DE60326264D1 (no)
ES (1) ES2323692T3 (no)
MX (1) MXPA05005909A (no)
NO (1) NO20052714L (no)
NZ (1) NZ540735A (no)
RU (1) RU2344144C2 (no)
WO (1) WO2004050111A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462325B2 (en) * 2001-11-30 2008-12-09 Nomadics, Inc. Luminescent polymer particles
US7361742B2 (en) * 2002-12-02 2008-04-22 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions
MX2007009219A (es) * 2005-02-04 2008-01-16 Survac Aps Vacuna de peptido de survivina.
US7858363B2 (en) * 2006-07-22 2010-12-28 Zymo Research Corporation Plasmid DNA isolation
KR100973428B1 (ko) * 2008-05-19 2010-08-03 한국과학기술연구원 말토오스 결합 단백질을 이용한 생리활성 폴리펩타이드의고정화 방법
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NO162210C (no) * 1987-07-20 1989-11-22 Fasting Biotech As Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a.
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH11507215A (ja) * 1995-06-05 1999-06-29 ノバルティス・アクチエンゲゼルシャフト アゴニスト活性を実質的にもたないＣ５ａ受容体アンタゴニストおよび製造方法
EP0859625B1 (en) * 1995-10-20 2008-06-25 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
WO2002030985A2 (en) * 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US7361742B2 (en) * 2002-12-02 2008-04-22 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions

Also Published As

Publication number Publication date
EP1569958B1 (en) 2009-02-18
EP1569958A2 (en) 2005-09-07
CN1745098A (zh) 2006-03-08
ES2323692T3 (es) 2009-07-23
US7361742B2 (en) 2008-04-22
RU2344144C2 (ru) 2009-01-20
KR20050090390A (ko) 2005-09-13
MXPA05005909A (es) 2005-08-26
RU2005120785A (ru) 2006-01-20
US20040214768A1 (en) 2004-10-28
NZ540735A (en) 2008-08-29
WO2004050111A2 (en) 2004-06-17
ATE423133T1 (de) 2009-03-15
CA2508302A1 (en) 2004-06-17
AU2003288472A1 (en) 2004-06-23
US20080262197A1 (en) 2008-10-23
WO2004050111A3 (en) 2004-07-29
JP2006507834A (ja) 2006-03-09
NO20052714D0 (no) 2005-06-06
DE60326264D1 (de) 2009-04-02

Similar Documents

Publication Publication Date Title
NO20052714L (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
CY1124137T1 (el) Μεθοδος για την παραγωγη αντισωματων περιοχης
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
NO20082905L (no) Anti-IL-17 antistoff
CL2009002004A1 (es) Anticuerpo o fragmento del mismo que se une al receptor de interleuquina 4 que comprende una region variable de cadena liviana y pesada; secuencias de acido nucleico que codifica dichas regiones; vector que comprende dicha secuencia; celula huesped; metodo para producir dicho anticuerpo; y uso de dicho anticuerpo para trastornos inmunologicos.
NO20055508L (no) Prostata stamcelleantigen (PSCA) varianter og subsekvenser derav
EA201301072A1 (ru) Антитела против il-23p19 и их применение
WO2004042017A3 (en) Methods and compositions for increasing antibody production
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
NO20065874L (no) Antistoffer og beslektede molekyler som bindes til PSCA proteiner
BRPI0606790C1 (pt) anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, composição, vetor de expressão, microrganismo transgênico, célula hospedeira procariótica, kit, e, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, ou de uma composição
BR0311471A (pt) anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
WO2007109686A3 (en) Immunomodulation of inflammatory conditions utilizing follistatin-like protein-1 and agents that bind thereto
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
WO2007016340A3 (en) Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
WO2008076255A3 (en) Canine thymic stromal lymphopoietin protein and uses thereof
DK1301539T3 (da) Antigenbindende fragmenter, der er specifikke for dendristiske celler, sammensætninger og fremgangsmåder til anvendelse deraf, antigener, der genkendes deraf, og celler opnået derved
DK1553832T3 (da) Præparater og fremgangsmåder til celleseparering
WO2004024750A3 (en) Cd44-binding ligands
WO2002010337A3 (en) Method of cloning porcine animals
ATE428771T1 (de) Antikörper gegen hundepankreaslipase
WO2007008708A3 (en) Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application